Primary Biliary Cholangitis Therapeutics Market By Drug type (Primary Drug, Secondary Drug), By Distribution Channel (Hospital Pharmacies, Drugs Stores and Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032

Primary Biliary Cholangitis Therapeutics Market By Drug type (Primary Drug, Secondary Drug), By Distribution Channel (Hospital Pharmacies, Drugs Stores and Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032


The primary biliary cholangitis therapeutics market was valued at $683.95 million in 2022 and is estimated to reach $1.36 billion by 2032, exhibiting a CAGR of 7.1% from 2023 to 2032. Primary Biliary Cholangitis (PBC) therapeutics refers to the various treatment options available for managing and treating the condition. Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is a chronic autoimmune liver disease that primarily affects the small bile ducts within the liver. It is characterized by inflammation, destruction, and scarring of these bile ducts, leading to impaired bile flow and subsequent liver damage. The exact cause of PBC is still unknown, but it is believed to result from a combination of genetic predisposition and environmental triggers. The immune system mistakenly targets the bile ducts, leading to their destruction and the accumulation of bile within the liver. Over time, this ongoing inflammation and bile duct damage may progress to cirrhosis (scarring of the liver tissue) and liver failure. The goal of PBC therapeutics is to improve liver function, slow down disease progression, alleviate symptoms, and prevent complications.

Major factors that drive the growth of the global primary biliary cholangitis therapeutics market include rapid advancements in treatment of primary biliary cholangitis; rise in number of research regarding primary biliary cholangitis therapeutics; and increase in number of patients suffering from primary biliary cholangitis. For instance, according to the review article “autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis,” published in June 2021, the prevalence of primary biliary cholangitis and primary sclerosing cholangitis disease ranges from 1.9 to 40.2 per 100,000 people and has also grown over time. The increased prevalence is probably attributable to a combination of better disease recognition and data collection, and increased survival after the introduction of ursodeoxycholic acid (UDCA). 

Furthermore, surge in demand for primary biliary cholangitis therapeutics, increase in number of awareness programs regarding primary biliary cholangitis, and rise in number of clinical trials for the development of primary biliary cholangitis therapeutics boost the growth of primary biliary cholangitis therapeutics market. For instance, in October 2021, COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles (CNPs) to treat immune disorders announced the U.S. FDA accepted an investigational new drug application (IND) for a proof-of-concept study of investigatory therapy CNP-104 of COUR Pharmaceuticals to address autoimmune causes of Primary Biliary Cholangitis (PBC). COUR nanoparticle platform (CNP) is a novel, proprietary system combining disease specific pathogenic antigens with state-of-the-art pharmaceutical nanoparticles that mimic normal removal of dead or dying cells from the body. PBC affects an estimated 130,000 people in the U.S., primarily women. Currently, healthcare professionals and patients rely on symptomatic therapies with limited results to slow down the progression of PBC but do not address its inherent cause, autoimmunity to PDC-E2 and the inflammatory cellular infiltration in the liver. This proof-of-concept trial will assess the safety and tolerability of CNP-104 in adults with PBC and aims to find the optimal dose level that strikes the best balance between safety and treatment activity.

In addition, increase in target population, rise in diagnosis rate of primary biliary cholangitis diseases, and surge in the prevalence of autoimmune diseases propel the market growth. However, lack of early diagnosis of primary biliary cholangitis, and limited treatment options are expected to restrict the growth of primary biliary cholangitis therapeutics market. On the contrary, surge in healthcare expenditure and unmet medical demands to get better treatment options in developing countries are expected to create lucrative opportunities for the expansion of the global market in the future. 

The primary biliary cholangitis therapeutics market is segmented on the basis of drug type, distribution channel, and region. On the basis of drug type, the market is bifurcated into primary drug and secondary drug. The primary drug segment is further categorized into obeticholic acid, ursodeoxycholic acid, others (PPARα/PPARδ agonist, and ileal bile acid transport inhibitors). On the basis of distribution channel, it is segregated into hospital pharmacies, drugs stores and retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

The major players profiled in the report are ABC Farmaceutici S.p.a., Alkem Laboratories Limited, AMAGEN INDIA LIFE SCIENCES, GENFIT, Intercept Pharmaceuticals, Inc., Ipsen Pharma, Leeford Healthcare Ltd, Lupin, Sun Pharmaceutical Industries Ltd., and Zydus Lifesciences Limited. These major players have adopted product approval, agreement, acquisition, and product launch as key developmental strategies to improve the product portfolio of the primary biliary cholangitis therapeutics market.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the primary biliary cholangitis therapeutics market analysis from 2022 to 2032 to identify the prevailing primary biliary cholangitis therapeutics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the primary biliary cholangitis therapeutics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global primary biliary cholangitis therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug type

Primary Drug
Type
Obeticholic Acid
Ursodeoxycholic Acid
Others
Secondary Drug

By Distribution Channel

Hospital Pharmacies
Drugs Stores and Retail Pharmacies
Online Pharmacies

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
ABC Farmaceutici S.p.a.
Alkem Laboratories Ltd.
AMAGEN INDIA LIFE SCIENCES
GENFIT
Intercept Pharmaceuticals, Inc.
Ipsen Pharma
Leeford Healthcare Limited
Lupin
Sun Pharmaceutical Industries Ltd
Zydus Lifesciences Limited

Please Note: It will take 7-10 business days to complete the report upon order confirmation.


CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in cases of primary biliary cholangitis
3.4.1.2. Rise in research and development
3.4.2. Restraints
3.4.2.1. Lack of early diagnosis and limited treatment options
3.4.3. Opportunities
3.4.3.1. Rise in adoption of key strategies
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Primary Drug
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.2.4. Primary Drug Primary Biliary Cholangitis Therapeutics Market by Type
4.3. Secondary Drug
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospital Pharmacies
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Drugs Stores and Retail Pharmacies
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Online Pharmacies
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key trends and opportunities
6.2.2. Market size and forecast, by Drug type
6.2.3. Market size and forecast, by Distribution Channel
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Key market trends, growth factors and opportunities
6.2.4.1.2. Market size and forecast, by Drug type
6.2.4.1.3. Market size and forecast, by Distribution Channel
6.2.4.2. Canada
6.2.4.2.1. Key market trends, growth factors and opportunities
6.2.4.2.2. Market size and forecast, by Drug type
6.2.4.2.3. Market size and forecast, by Distribution Channel
6.2.4.3. Mexico
6.2.4.3.1. Key market trends, growth factors and opportunities
6.2.4.3.2. Market size and forecast, by Drug type
6.2.4.3.3. Market size and forecast, by Distribution Channel
6.3. Europe
6.3.1. Key trends and opportunities
6.3.2. Market size and forecast, by Drug type
6.3.3. Market size and forecast, by Distribution Channel
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Key market trends, growth factors and opportunities
6.3.4.1.2. Market size and forecast, by Drug type
6.3.4.1.3. Market size and forecast, by Distribution Channel
6.3.4.2. France
6.3.4.2.1. Key market trends, growth factors and opportunities
6.3.4.2.2. Market size and forecast, by Drug type
6.3.4.2.3. Market size and forecast, by Distribution Channel
6.3.4.3. UK
6.3.4.3.1. Key market trends, growth factors and opportunities
6.3.4.3.2. Market size and forecast, by Drug type
6.3.4.3.3. Market size and forecast, by Distribution Channel
6.3.4.4. Italy
6.3.4.4.1. Key market trends, growth factors and opportunities
6.3.4.4.2. Market size and forecast, by Drug type
6.3.4.4.3. Market size and forecast, by Distribution Channel
6.3.4.5. Spain
6.3.4.5.1. Key market trends, growth factors and opportunities
6.3.4.5.2. Market size and forecast, by Drug type
6.3.4.5.3. Market size and forecast, by Distribution Channel
6.3.4.6. Rest of Europe
6.3.4.6.1. Key market trends, growth factors and opportunities
6.3.4.6.2. Market size and forecast, by Drug type
6.3.4.6.3. Market size and forecast, by Distribution Channel
6.4. Asia-Pacific
6.4.1. Key trends and opportunities
6.4.2. Market size and forecast, by Drug type
6.4.3. Market size and forecast, by Distribution Channel
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Key market trends, growth factors and opportunities
6.4.4.1.2. Market size and forecast, by Drug type
6.4.4.1.3. Market size and forecast, by Distribution Channel
6.4.4.2. China
6.4.4.2.1. Key market trends, growth factors and opportunities
6.4.4.2.2. Market size and forecast, by Drug type
6.4.4.2.3. Market size and forecast, by Distribution Channel
6.4.4.3. Australia
6.4.4.3.1. Key market trends, growth factors and opportunities
6.4.4.3.2. Market size and forecast, by Drug type
6.4.4.3.3. Market size and forecast, by Distribution Channel
6.4.4.4. India
6.4.4.4.1. Key market trends, growth factors and opportunities
6.4.4.4.2. Market size and forecast, by Drug type
6.4.4.4.3. Market size and forecast, by Distribution Channel
6.4.4.5. South Korea
6.4.4.5.1. Key market trends, growth factors and opportunities
6.4.4.5.2. Market size and forecast, by Drug type
6.4.4.5.3. Market size and forecast, by Distribution Channel
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Key market trends, growth factors and opportunities
6.4.4.6.2. Market size and forecast, by Drug type
6.4.4.6.3. Market size and forecast, by Distribution Channel
6.5. LAMEA
6.5.1. Key trends and opportunities
6.5.2. Market size and forecast, by Drug type
6.5.3. Market size and forecast, by Distribution Channel
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Key market trends, growth factors and opportunities
6.5.4.1.2. Market size and forecast, by Drug type
6.5.4.1.3. Market size and forecast, by Distribution Channel
6.5.4.2. Saudi Arabia
6.5.4.2.1. Key market trends, growth factors and opportunities
6.5.4.2.2. Market size and forecast, by Drug type
6.5.4.2.3. Market size and forecast, by Distribution Channel
6.5.4.3. South Africa
6.5.4.3.1. Key market trends, growth factors and opportunities
6.5.4.3.2. Market size and forecast, by Drug type
6.5.4.3.3. Market size and forecast, by Distribution Channel
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Key market trends, growth factors and opportunities
6.5.4.4.2. Market size and forecast, by Drug type
6.5.4.4.3. Market size and forecast, by Distribution Channel
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. Intercept Pharmaceuticals, Inc.
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. Lupin
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Zydus Lifesciences Limited
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Sun Pharmaceutical Industries Ltd
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.5. Leeford Healthcare Limited
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.6. Alkem Laboratories Ltd.
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.7. AMAGEN INDIA LIFE SCIENCES
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.8. GENFIT
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. Ipsen Pharma
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. ABC Farmaceutici S.p.a.
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 02. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR PRIMARY DRUG, BY REGION, 2022-2032 ($MILLION)
TABLE 03. GLOBAL PRIMARY DRUG PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 04. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR SECONDARY DRUG, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 06. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 07. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 08. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 09. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 10. NORTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 11. NORTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 12. NORTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 13. U.S. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 14. U.S. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 15. CANADA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 16. CANADA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 17. MEXICO PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 18. MEXICO PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 19. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 20. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 21. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 22. GERMANY PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 23. GERMANY PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 24. FRANCE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 25. FRANCE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 26. UK PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 27. UK PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 28. ITALY PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 29. ITALY PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 30. SPAIN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 31. SPAIN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 32. REST OF EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 33. REST OF EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 34. ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 35. ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 36. ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 37. JAPAN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 38. JAPAN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 39. CHINA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 40. CHINA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 41. AUSTRALIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 42. AUSTRALIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 43. INDIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 44. INDIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 45. SOUTH KOREA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 46. SOUTH KOREA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 47. REST OF ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 48. REST OF ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 49. LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 50. LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 51. LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 52. BRAZIL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 53. BRAZIL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 54. SAUDI ARABIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 55. SAUDI ARABIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 56. SOUTH AFRICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 57. SOUTH AFRICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 58. REST OF LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 59. REST OF LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 60. INTERCEPT PHARMACEUTICALS, INC.: KEY EXECUTIVES
TABLE 61. INTERCEPT PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 62. INTERCEPT PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
TABLE 63. INTERCEPT PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 64. INTERCEPT PHARMACEUTICALS, INC.: KEY STRATERGIES
TABLE 65. LUPIN: KEY EXECUTIVES
TABLE 66. LUPIN: COMPANY SNAPSHOT
TABLE 67. LUPIN: PRODUCT SEGMENTS
TABLE 68. LUPIN: PRODUCT PORTFOLIO
TABLE 69. LUPIN: KEY STRATERGIES
TABLE 70. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
TABLE 71. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
TABLE 72. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
TABLE 73. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
TABLE 74. ZYDUS LIFESCIENCES LIMITED: KEY STRATERGIES
TABLE 75. SUN PHARMACEUTICAL INDUSTRIES LTD: KEY EXECUTIVES
TABLE 76. SUN PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
TABLE 77. SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCT SEGMENTS
TABLE 78. SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
TABLE 79. LEEFORD HEALTHCARE LIMITED: KEY EXECUTIVES
TABLE 80. LEEFORD HEALTHCARE LIMITED: COMPANY SNAPSHOT
TABLE 81. LEEFORD HEALTHCARE LIMITED: PRODUCT SEGMENTS
TABLE 82. LEEFORD HEALTHCARE LIMITED: PRODUCT PORTFOLIO
TABLE 83. ALKEM LABORATORIES LTD.: KEY EXECUTIVES
TABLE 84. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 85. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS
TABLE 86. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 87. AMAGEN INDIA LIFE SCIENCES: KEY EXECUTIVES
TABLE 88. AMAGEN INDIA LIFE SCIENCES: COMPANY SNAPSHOT
TABLE 89. AMAGEN INDIA LIFE SCIENCES: PRODUCT SEGMENTS
TABLE 90. AMAGEN INDIA LIFE SCIENCES: PRODUCT PORTFOLIO
TABLE 91. GENFIT: KEY EXECUTIVES
TABLE 92. GENFIT: COMPANY SNAPSHOT
TABLE 93. GENFIT: PRODUCT SEGMENTS
TABLE 94. GENFIT: PRODUCT PORTFOLIO
TABLE 95. GENFIT: KEY STRATERGIES
TABLE 96. IPSEN PHARMA: KEY EXECUTIVES
TABLE 97. IPSEN PHARMA: COMPANY SNAPSHOT
TABLE 98. IPSEN PHARMA: PRODUCT SEGMENTS
TABLE 99. IPSEN PHARMA: PRODUCT PORTFOLIO
TABLE 100. IPSEN PHARMA: KEY STRATERGIES
TABLE 101. ABC FARMACEUTICI S.P.A.: KEY EXECUTIVES
TABLE 102. ABC FARMACEUTICI S.P.A.: COMPANY SNAPSHOT
TABLE 103. ABC FARMACEUTICI S.P.A.: PRODUCT SEGMENTS
TABLE 104. ABC FARMACEUTICI S.P.A.: PRODUCT PORTFOLIO
TABLE 105. ABC FARMACEUTICI S.P.A.: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET (2023-2032)
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW THREAT OF NEW ENTRANTS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW INTENSITY OF RIVALRY
FIGURE 08. LOW BARGAINING POWER OF BUYERS
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALPRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET
FIGURE 09. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2022(%)
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR PRIMARY DRUG, BY COUNTRY 2022 AND 2032(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR SECONDARY DRUG, BY COUNTRY 2022 AND 2032(%)
FIGURE 12. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET BY REGION, 2022
FIGURE 17. U.S. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 18. CANADA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 19. MEXICO PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 20. GERMANY PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 21. FRANCE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 22. UK PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 23. ITALY PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 24. SPAIN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 25. REST OF EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 26. JAPAN PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 27. CHINA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 28. AUSTRALIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 29. INDIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 30. SOUTH KOREA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 31. REST OF ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 32. BRAZIL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 33. SAUDI ARABIA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 34. SOUTH AFRICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 35. REST OF LAMEA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 36. TOP WINNING STRATEGIES, BY YEAR
FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 39. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 40. COMPETITIVE DASHBOARD
FIGURE 41. COMPETITIVE HEATMAP: PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET
FIGURE 42. TOP PLAYER POSITIONING, 2022
FIGURE 43. INTERCEPT PHARMACEUTICALS, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 44. LUPIN: NET SALES, 2020-2022 ($MILLION)
FIGURE 45. LUPIN: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 46. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 47. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 48. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 49. SUN PHARMACEUTICAL INDUSTRIES LTD: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 50. SUN PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 51. ALKEM LABORATORIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 52. ALKEM LABORATORIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 53. GENFIT: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 54. IPSEN PHARMA: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 55. IPSEN PHARMA: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 56. IPSEN PHARMA: REVENUE SHARE BY REGION, 2022 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings